Michael Dees

Michael leads Lindsay Goldberg’s business services vertical and its investment activities in Europe, and co-leads the industrials vertical. He has led some of Lindsay Goldberg’s most successful investments and serves on the board of directors of several Lindsay Goldberg portfolio companies, including Creation Technologies, Liveo Research, Stelco Holdings, Summit Interconnect, Galen Mental Health, and Doppler Veterinary Network. Prior to joining Lindsay Goldberg, Michael worked at Morgan Stanley.

At MMS, Michael supports the leadership team in implementing various initiatives, including business-related strategy. Michael earned his MBA from Harvard Business School, where he was a George F. Baker Scholar, and his B.A. in Economics from Harvard College.

Suggested For You

perspectives

May 6th, 2025

Why Clinical Trial Simulation Is Reshaping Drug Development: A Q&A with Dr. Aiden Flynn

perspectives

April 24th, 2025

How to Derisk Clinical Development with Unified Trial Design and Regulatory Strategy

perspectives

April 8th, 2025

Updated UK Clinical Trial Regulation: The Key Changes and Impact on Development Safety Update Report (DSUR) Requirements

news

April 3rd, 2025

Datacise by MMS Wins 2025 Data Breakthrough Award for Best Data Science Solution

perspectives

March 27th, 2025

Enhancing Drug Safety Through Digital Solutions: Innovative Technologies in FDA REMS Programs

news

March 19th, 2025

MMS REMS-focused Technology bolsters Full-Service REMS Solutions

webinar

April 30th, 2025

Advancing Clinical Development with Innovative Trial Design and Regulatory Strategies

perspectives

March 6th, 2025

Overview of FDA Guidance for Industry on Assessment of Ovarian Toxicity in Premenopausal Adults During Development for Oncologic Products

webinar

March 25th, 2025

Overcoming NDA/BLA Submission Challenges: Practical Strategies for Success

perspectives

February 13th, 2025

Helping European Drug Development Companies Succeed in the US Market

news

February 12th, 2025

MMS Acquires Exploristics and KerusCloud Simulation Platform to Expand Biostatistics and Data Science Capabilities as a Global Data-Focused CRO

perspectives

January 30th, 2025

Post-PDUFA VII Updates: FDA Meetings Public Workshop & Lessons Learned